Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

Patients with highly active relapsing-remitting multiple sclerosis (RRMS) are at greater risk for disease progression and may respond differently to MS therapeutics than those with less active disease. The current post hoc analysis evaluated the effects of daclizumab high-yield process (DAC HYP) vs....

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannoni, Gavin, Radue, Ernst-Wilhelm, Havrdova, Eva, Riester, Katherine, Greenberg, Steven, Mehta, Lahar, Elkins, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915085/
https://www.ncbi.nlm.nih.gov/pubmed/24375015
http://dx.doi.org/10.1007/s00415-013-7196-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915085/
https://www.ncbi.nlm.nih.gov/pubmed/24375015
http://dx.doi.org/10.1007/s00415-013-7196-4

Ejemplares similares